Skip to content
DataLookout
Menu

NCT07938073

Phase 2 Study Of IDH 1/2 Inhibitor Vorasidenib In Patients With IDH2-Mutated Intrahepatic Cholangiocarcinoma

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Safety and adverse events (AEs
Timeframe: Through study completion; an average of 1 year.

Arms and interventions

Safety Run-In/ExpansionExperimental

Treatment with Vorasidenib (PO) Q4W

Drugs: Vorasidenib

Sites

1 site in 1 country

  • UT MD Anderson Cancer CenterHouston, Texas, United States